Table 3.
Time-to-seizure occurrence by multivariable proportional hazard regression analysis in patients in the LUMINA cohort*
Variable | HR (95% CI) | p Value |
---|---|---|
Younger age, years | 1.04 (1.00 to 1.08) | 0.0304 |
SLAM-R† | 1.10 (1.04 to 1.15) | 0.0004 |
Mucocutaneous manifestations | 0.34 (0.16 to 0.41) | 0.0039 |
Hydroxychloroquine use | 0.35 (0.15 to 0.80) | 0.0131 |
LUMINA, LUpus in MInorities: NAture versus Nurture.
Adjusted for gender, ethnicity, marital status, disease duration, damage accrual (seizures excluded), disease manifestations (musculoskeletal, psychosis and renal damage) and medications (cyclophosphamide, average dose of glucocorticoids).
Systemic Lupus Activity Measure-Revised at baseline (secures excluded).
For alternative analyses, please refer to text.